Livzon Pharmaceutical Group Inc Class H released its earnings results on Oct 23, 2024. The company reported $0.075 earnings per share for the quarter, missing the consensus estimate of $0.079 by -$0.004.

Is Livzon Pharmaceutical Group Inc Class H overvalued?

According to Wall Street analysts Livzon Pharmaceutical Group Inc Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Livzon Pharmaceutical Group Inc Class H pay dividends?

Livzon Pharmaceutical Group Inc Class H pays a Annually dividend of $0.19 which represents an annual dividend yield of 5.64%. See more information on Livzon Pharmaceutical Group Inc Class H dividends here

What is Livzon Pharmaceutical Group Inc Class H’s EPS estimate?

Livzon Pharmaceutical Group Inc Class H’s EPS estimate is $0.06.

How many shares outstanding does Livzon Pharmaceutical Group Inc Class H have?

Livzon Pharmaceutical Group Inc Class H has 307,052,430 shares outstanding.

What happened to Livzon Pharmaceutical Group Inc Class H’s price movement after its last earnings report?

Livzon Pharmaceutical Group Inc Class H reported an EPS of $0.075 in its last earnings report, missing expectations of $0.079. Following the earnings report the stock price went down -1.366%.

Which hedge fund is a major shareholder of Livzon Pharmaceutical Group Inc Class H?

Currently, no hedge funds are holding shares in LVZPF

---

Livzon Pharmaceutical Group Stock Smart Score

Unlock Smart Score

Analyst Consensus

Moderate Sell

Average Price Target:
$2.96 (-18.46% Downside)

Technicals

Fundamentals

Return on Equity

14.46%

Trailing 12-Months

Asset Growth

4.56%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Livzon Pharmaceutical Group Inc Class H

Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio primarily comprises of western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drugs address serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, as well as blood and hemopoietic system. The Company distributes its products within domestic market and to overseas markets.

---

LVZPF Stock 12 Month Forecast

Average Price Target

$2.96

▼(-18.46% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","1.75":"$1.75","2.5":"$2.5","3.25":"$3.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.95535809,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.95535809,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.96</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,1.75,2.5,3.25,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.41,3.3750275453846155,3.340055090769231,3.305082636153846,3.2701101815384614,3.2351377269230768,3.200165272307692,3.165192817692308,3.130220363076923,3.0952479084615385,3.060275453846154,3.025302999230769,2.9903305446153845,{"y":2.95535809,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.41,3.3753846153846156,3.3407692307692307,3.306153846153846,3.2715384615384617,3.236923076923077,3.2023076923076923,3.167692307692308,3.1330769230769233,3.0984615384615384,3.063846153846154,3.029230769230769,2.9946153846153845,{"y":2.96,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.41,3.3750275453846155,3.340055090769231,3.305082636153846,3.2701101815384614,3.2351377269230768,3.200165272307692,3.165192817692308,3.130220363076923,3.0952479084615385,3.060275453846154,3.025302999230769,2.9903305446153845,{"y":2.95535809,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.43,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.42,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.19,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.27,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.92,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.01,"date":1700179200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1701388800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1728604800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

Takeda Pharmaceutical Company

―

ZTS

Zoetis

―

NVS

Novartis

―

SHTDF

Sinopharm Group Co

―

Compare LVZPF Stocks >

Best Analysts Covering LVZPF

1 Year

Sean Wu CFAMorgan Stanley

1 Year Success Rate

3/4 ratings generated profit

1 Year Average Return

+5.10%

reiterated a sell rating 29 days ago

Copying Sean Wu CFA's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +5.10% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing